Eli Lilly and Company today will announce the launch of its publicly available clinical trial registry, www.lillytrials.com, which will post the r
Dr. Paolo Renzi, Topigen's Chief Scientific Director, announced that after reviewing Topigen's submission, the Food and Drug Administration (FDA) has stated that a Phase 1 clinical trial can be initia
Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays, as these assays offer a more accurate representation of the real-life cell model than the traditional enzyme- or antibody-based as
Every day, people suffer traumatic experiences that scar their minds. Combat, rape, bombings, burns, beatings, and horrific car accidents haunt them with
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients wit
Metabolic Pharmaceuticals Limited today announced the success of its Phase 2b human trial of AOD9604 for obesity.The AOD9604 molecule is a small orally active peptide modelled on one sect
Pfizer today announced results of a comprehensive six-year review of efficacy and safety data for Detrol LA (tolterodine tartrate extended release capsules) indicating that
In light of several recent drug industry scandals roiling the nation's public health and raising serious questions about the US bodies that license and regulate the industry -- and startling new revelations today concerning National Institutes of Healt
Merck & Co., Inc. today announced that the Food and Drug Administration (FDA) has approved changes to the prescribing information for PROSCAR? (finasteride) based on a landmark
GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the B
The Pharmacy Care Alliance (PCA) today announced that AstraZeneca, Johnson & Johnson Pharmaceutical Companies, Inc., Eli Lilly and Company, Merck and Novartis will make many prescription drugs available to qualifying PCA Medicare discount cardholders free of charges from the manufacturer plus a nominal amount to cover dispensing, processing and other costs.
A PCA cardholder whose income is 135 percent or less of the federal poverty level and who qualifies for the federal government's $600 annual prescription drug purchase credit will receive the additional savings after he or she has fully depleted their $600 credit. The nominal amount paid by qualified PCA Medicare prescription discount card enrollees to cover dispensing, processing and other costs will be in the range of $10 to $12 for each prescription depending on the manufacturer, drug and pharmacy. In some cases, the payment could be as low as $5.
Under the Medicare prescription discount card program, while enrollees are still using their $600 credit, copayments are similar -- either five or ten percent of the discounted price of the prescription drug. Enrollees whose income is between 100 and 135 percent of the federal poverty level pay ten percent. Those with incomes below 100 percent pay five percent. "In making additional significant savings easily available to the Medicare beneficiaries most in need of assistance with their drug costs, these five manufacturers have made the PCA Medicare prescription discount card even more valuable and easy to use," said Mary Ann Wagner, President of the Pharmacy Care Alliance. "Also very important, this added benefit continues to be available at the PCA cardholder's local neighborhood network pharmacy," observed Wagner. She emphasized that Medicare beneficiaries who qualify for the $600 credit and thus the manufacturers' additional savings should not delay applying for the Pharmacy Care Alliance Medicare prescription discount card. Medicare-approved drug discount cards are designed to help beneficiaries with prescription drug costs until the new federal prescription drug coverage -- Medicare Part D -- takes effect in January 2006. The Pharmacy Care Alliance The Pharmacy Care Alliance is a not-for-profit 501 (c) (6) organization.
It is an alliance between the National Association of Chain Drug Stores, Inc. (NACDS), which represents 216 chain pharmacies operating more than 35,000 retail community pharmacies, and Express Scripts, Inc., one of the largest pharmacy benefit managers in North America. The Pharmacy Care Alliance discount card will be supported by neighborhood pharmacists in its network of more than 43,000 participating pharmacies, who will provide support and counsel to program members and advise on ways to lower overall prescription drug costs. For more information, visit http://www.pcacard.com.